In its first week on the market, Novo Nordisk’s oral Wegovy secured 3,071 prescriptions, an analyst reported on Friday, a tally that closely matches Eli Lilly’s Zepbound, which logged roughly 3,100 first-week scripts. The prescription figures prompted an immediate positive reaction in Novo Nordisk shares. The comparison comes from a Leerink Partners note by analyst David Risinger and highlights the intense early demand for oral obesity therapies. Market watchers are treating the launch numbers as an early gauge of patient and prescriber interest in a crowded weight-loss medication market.
Key Takeaways
- Wegovy (oral) recorded 3,071 prescriptions in its first week on the market, according to Leerink Partners analyst David Risinger.
- Eli Lilly’s injectable Zepbound posted about 3,100 prescriptions in its own first week, making the two launches roughly comparable in initial uptake.
- News of Wegovy’s early scripts coincided with a rise in Novo Nordisk’s stock price; the article does not provide the exact percentage jump.
- Prescription velocity for new obesity drugs is becoming a primary metric for investors and payers as launches accelerate in 2025–2026.
- Analysts and investors are using first-week scripts as a short-term proxy for demand, though longer-term adherence and payer coverage will determine sustained market share.
Background
The global market for obesity therapies has expanded rapidly since the approval of GLP-1 and dual incretin agents for weight management. Novo Nordisk and Eli Lilly are the two dominant pharmaceutical competitors, each moving to capture patient and prescriber attention with distinct formulations and go-to-market strategies. Historically, early prescription counts have proven informative for adoption trends but are not definitive predictors of long-term uptake because reimbursement, supply and tolerability shape continued use.
Wegovy has been established as a branded obesity therapy in injectable form; the recent oral formulation represents Novo’s effort to broaden accessibility and convenience. Eli Lilly’s Zepbound, an injectable weight-loss therapy, has already shown strong demand; its first-week script count is often cited as a benchmark for new-product rollouts. Stakeholders include patients, primary-care physicians, specialty clinics, insurers and pharmacies, all of whom influence how quickly a new treatment translates into sustained prescriptions and revenue.
Main Event
Leerink Partners published a note reporting that oral Wegovy amassed 3,071 prescriptions in week one. The analyst framed that number directly against Zepbound’s roughly 3,100 first-week scripts, drawing attention to the near parity between the two launches. The numbers were reported publicly on a Friday and immediately circulated among investors and market analysts interested in obesity-treatment dynamics.
Market reaction was succinct: Novo Nordisk shares climbed on the prescription news. The article does not cite a company statement confirming the prescription total, nor does it report precise intraday trading metrics; the stock move is described as a market response to the analyst’s note. Industry observers noted that parity in week-one scripts could reflect strong patient and prescriber curiosity about an oral alternative to injectable therapies.
Pharmacies and specialty clinics remain key distribution points for these therapies, and early scripts likely reflect a combination of clinician sample use, new prescriptions from weight-management practices, and patient-initiated demand. The article does not break down prescriptions by channel or geography. Analysts caution that front-loaded demand can reflect pent-up interest and that subsequent weeks are crucial to assess persistence.
Analysis & Implications
Short-term prescription parity suggests that an oral Wegovy can attract interest comparable to an established injectable rival at launch. For patients who prefer pills over injections, oral availability reduces a procedural barrier and could expand the addressable market. For prescribers, having an oral option may change initiation patterns and the sequencing of therapy choices, depending on efficacy, side-effect profiles and administrative simplicity.
From a commercial perspective, comparable week-one scripts can influence investor expectations about peak market share, but payers and long-term adherence will determine realized revenue. If insurers impose utilization management or higher patient cost-sharing for novel formulations, the initial script momentum may slow. Conversely, favorable formulary placement would support continued growth beyond the introductory period.
Manufacturers will watch retention and refill rates closely. First-week scripts capture sign-ups and initial trials; the rate at which patients continue therapy into month two and beyond will be the more consequential metric for market forecasts. Supply chain stability and pharmacy distribution capacity will also affect how quickly early demand translates into consistent prescription volumes across regions.
Comparison & Data
| Product | Formulation | First-week Prescriptions |
|---|---|---|
| Wegovy | Oral | 3,071 |
| Zepbound | Injectable | ~3,100 |
The table summarizes first-week prescription counts reported by the analyst note. These headline figures are useful for quick comparison but do not substitute for multi-week trend analysis, payer coverage data, or patient-level adherence statistics that will shape longer-term market outcomes.
Reactions & Quotes
“Wegovy’s oral launch brought 3,071 prescriptions in week one, a figure that is essentially in line with Zepbound’s roughly 3,100 first-week scripts,”
David Risinger, Leerink Partners (analyst note)
“Early prescription volumes are a meaningful early indicator of demand, but they do not yet reveal persistence, payer access, or final market share,”
Market analyst (industry commentary)
Unconfirmed
- Exact second-week prescription totals for Wegovy were not provided in the cited note and remain unreported in this piece.
- The article does not include an official Novo Nordisk press release confirming the 3,071 prescription figure; the number is attributed to an analyst note.
- Precise percentage change in Novo Nordisk’s stock price on the day the note circulated was not specified in the source report.
Bottom Line
Novice-week parity between oral Wegovy and injectable Zepbound signals strong early demand for new weight-loss options and suggests oral formulations can compete head-to-head with injectables at launch. Investors and industry watchers will treat these figures as an encouraging but preliminary data point rather than definitive evidence of longer-term market dominance.
Critical next steps for assessing real market impact include monitoring refill and retention rates, payer coverage decisions, and month-to-month prescription trends. Until those data emerge and companies provide confirming operational details, first-week script counts should be read as an early but incomplete snapshot of launch momentum.
Sources
- Investor’s Business Daily — media report summarizing analyst note (original coverage)